<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644068</url>
  </required_header>
  <id_info>
    <org_study_id>D9720C00001</org_study_id>
    <nct_id>NCT04644068</nct_id>
  </id_info>
  <brief_title>Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies</brief_title>
  <acronym>PETRA</acronym>
  <official_title>A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is designed to determine if experimental treatment with PARP inhibitor,&#xD;
      AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has&#xD;
      anti-cancer activity in patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase I/IIa modular, open-label, multi-center study of AZD5305 administered&#xD;
      orally, either as monotherapy or in combination with other anti-cancer agents in patients&#xD;
      with advanced solid malignancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">July 25, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study consists of individual modules each evaluating the safety and tolerability of AZD5305 dosed as monotherapy, or with a specific combination partner:&#xD;
Module 1 (AZD5305 monotherapy)&#xD;
Module 2 (AZD5305 in combination with paclitaxel)&#xD;
Module 3 (AZD5305 in combination with carboplatin, with or without paclitaxel) Each Module has 2 study parts: Part A consisting of dose-escalation cohorts and Part B, consisting of expansion cohorts.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects with adverse events/serious adverse events</measure>
    <time_frame>From time of Informed Consent to 28 days post last dose (approximately 1 year)</time_frame>
    <description>Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.</measure>
    <time_frame>From first dose of study treatment until the end of Cycle 1. Approximately 35 days.</time_frame>
    <description>A DLT is defined as any toxicity that occurs from the first dose of study treatment (either AZD5305 or combination anti-cancer agent) up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation and which includes pre-defined haematological, cardiac and non-haematological toxicities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best percentage change in target lesion</measure>
    <time_frame>From Screening to confirmed progressive disease (approximately 1 year)</time_frame>
    <description>Change in target lesion size from baseline, as defined by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>From Screening to confirmed progressive disease (approximately 1 year)</time_frame>
    <description>Best response until progression, as defined by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From Screening to confirmed progressive disease (approximately 1 year)</time_frame>
    <description>Time from response to progression, as defined by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From Screening to confirmed progressive disease (approximately 1 year)</time_frame>
    <description>Time from C1D1 to progression or death, as defined by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Response</measure>
    <time_frame>From Screening to confirmed progressive disease (approximately 1 year)</time_frame>
    <description>Time from C1D1 to complete or partial response, as defined by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of AZD5305 on Ph2AX (Ser139) PD biomarker</measure>
    <time_frame>From Cycle 0 Day 1 to Cycle 1 Day 15 (approximately 21 days)</time_frame>
    <description>Measure change from baseline in pH2AX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA125 response (ovarian cancer)</measure>
    <time_frame>From Screening to confirmed progressive disease (approximately 1 year)</time_frame>
    <description>at least a 50% reduction in CA125 levels from a pre-treatment sample as defined by GCIG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 1: Area Under Curve (AUC)</measure>
    <time_frame>At predefined intervals throughout the treatment period (approximately 12 weeks)</time_frame>
    <description>The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 1: Maximum plasma concentration of the drug (Cmax)</measure>
    <time_frame>At predefined intervals throughout the treatment period (approximately 12 weeks)</time_frame>
    <description>The concentration of AZD5305 in plasma will be determined (Cmax will be derived).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 1: The time taken to reach the maximum concentration (Tmax)</measure>
    <time_frame>At predefined intervals throughout the treatment period (approximately 12 weeks)</time_frame>
    <description>The concentration of AZD5305 in plasma will be determined (Tmax will be derived).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 1: Objective Response Rate(prostate cancer)</measure>
    <time_frame>From Screening to confirmed progressive disease (approximately 1 year)</time_frame>
    <description>Best response until progression, as defined by RECIST 1.1 or PCWG3(bone)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 1: Radiographic progression free survival (prostate cancer)</measure>
    <time_frame>From Screening to confirmed progressive disease (approximately 1 year)</time_frame>
    <description>Time from C1D1 to progression or death, as defined by RECIST 1.1 and PCWG3(bone).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 1: Proportion of subjects with â‰¥ 50% PSA decrease (prostate cancer)</measure>
    <time_frame>From Screening to confirmed progressive disease (approximately 1 year)</time_frame>
    <description>PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 2: Area Under Curve (AUC)</measure>
    <time_frame>At predefined intervals throughout the treatment period (approximately 12 weeks)</time_frame>
    <description>The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 2: Maximum plasma concentration of the drug (Cmax)</measure>
    <time_frame>At predefined intervals throughout the treatment period (approximately 12 weeks)</time_frame>
    <description>The concentration of AZD5305 in plasma will be determined (Cmax will be derived).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 2: The time taken to reach the maximum concentration (Tmax)</measure>
    <time_frame>At predefined intervals throughout the treatment period (approximately 12 weeks)</time_frame>
    <description>The concentration of AZD5305 in plasma will be determined (Tmax will be derived).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 3: Area Under Curve (AUC)</measure>
    <time_frame>At predefined intervals throughout the treatment period (approximately 12 weeks)</time_frame>
    <description>The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 3: Maximum plasma concentration of the drug (Cmax)</measure>
    <time_frame>At predefined intervals throughout the treatment period (approximately 12 weeks)</time_frame>
    <description>The concentration of AZD5305 in plasma will be determined (Cmax will be derived).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Module 3: The time taken to reach the maximum concentration (Tmax)</measure>
    <time_frame>At predefined intervals throughout the treatment period (approximately 12 weeks)</time_frame>
    <description>The concentration of AZD5305 in plasma will be determined (Tmax will be derived).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">715</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Module 1: AZD5305 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5305 Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 2: AZD5305 + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5305 + Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 3: AZD5305 + Carboplatin with or without Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5305 + Carboplatin with or without Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5305</intervention_name>
    <description>Oral PARP inhibitor</description>
    <arm_group_label>Module 1: AZD5305 Monotherapy</arm_group_label>
    <arm_group_label>Module 2: AZD5305 + Paclitaxel</arm_group_label>
    <arm_group_label>Module 3: AZD5305 + Carboplatin with or without Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV Anti-microtubule agent</description>
    <arm_group_label>Module 2: AZD5305 + Paclitaxel</arm_group_label>
    <arm_group_label>Module 3: AZD5305 + Carboplatin with or without Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Platinum chemotherapeutic</description>
    <arm_group_label>Module 3: AZD5305 + Carboplatin with or without Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 at the time of screening&#xD;
&#xD;
          -  Histological or cytological confirmation of advanced malignancy considered to be&#xD;
             suitable for study treatment and meeting module specific eligibility criteria..&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance status (ECOG PS: 0-2)&#xD;
&#xD;
          -  Life expectancy â‰¥ 12 weeks&#xD;
&#xD;
          -  Progressive cancer at the time of study entry&#xD;
&#xD;
          -  Patients must have evaluable disease as defined in module-specific criteria for Part A&#xD;
             and Part B&#xD;
&#xD;
          -  Adequate organ and marrow function as defined by the protocol.&#xD;
&#xD;
          -  For Part B expansion cohorts: Provision of formalin-fixed and paraffin embedded (FFPE)&#xD;
             tumour specimen is mandatory, where available, except if stated that it is optional in&#xD;
             a specific Module.&#xD;
&#xD;
        For Part A:&#xD;
&#xD;
        - Patients may have received up to one prior line of therapy with a PARPi-based regimen&#xD;
        (either as a treatment or as maintenance)&#xD;
&#xD;
        For Part B:&#xD;
&#xD;
        - Patients must not have received prior therapy with a PARPi-based regimen (either as a&#xD;
        treatment or as maintenance).&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any of the following:&#xD;
&#xD;
               1. Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment&#xD;
&#xD;
               2. Any investigational agents or study drugs from a previous clinical study within 5&#xD;
                  half-lives or 3 weeks (whichever is shorter) of the first dose of study treatment&#xD;
&#xD;
               3. Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the&#xD;
                  first dose of study treatment&#xD;
&#xD;
               4. Any live virus or bacterial vaccine within 28 days of the first dose of study&#xD;
                  treatment&#xD;
&#xD;
          -  Concomitant use of medications or herbal supplements known to be cytochrome P450 3A4&#xD;
             (CYP3A4) strong and moderate inhibitors or inducers.&#xD;
&#xD;
          -  Concomitant use of drugs that are known to prolong or shorten QT and have a known risk&#xD;
             of Torsades de Pointes.&#xD;
&#xD;
          -  Receiving continuous corticosteroids at a dose of &gt;10 mg prednisone/day or equivalent&#xD;
             for any reason.&#xD;
&#xD;
          -  Major surgery within 4 weeks of the first dose of study treatment.&#xD;
&#xD;
          -  Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a&#xD;
             limited field of radiation for palliation within 2 weeks of the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Any history of persisting (&gt; 2 weeks) severe pancytopenia due to any cause&#xD;
&#xD;
          -  Spinal cord compression or brain metastases unless asymptomatic, treated and stable&#xD;
             and not requiring continuous corticosteroids at a dose of &gt;10mg prednisone/day or&#xD;
             equivalent for at least 4 weeks prior to start of study treatment&#xD;
&#xD;
          -  Cardiac conditions as defined by the clinical study protocol&#xD;
&#xD;
          -  Other cardiovascular diseases as defined by any of the following:&#xD;
&#xD;
               1. Symptomatic heart failure,&#xD;
&#xD;
               2. uncontrolled hypertension,&#xD;
&#xD;
               3. hypertensive heart disease with significant left ventricular hypertrophy&#xD;
&#xD;
               4. acute coronary syndrome (ACS)/acute myocardial infarction (AMI), unstable angina&#xD;
                  pectoris, coronary intervention procedure with percutaneous coronary intervention&#xD;
                  (PCI) or coronary artery bypass grafting (CABG) within 6 months.&#xD;
&#xD;
               5. cardiomyopathy of any etiology&#xD;
&#xD;
               6. presence of clinically significant valvular heart disease&#xD;
&#xD;
               7. history of atrial or ventricular arrhythmia requiring treatment.&#xD;
&#xD;
               8. subjects with atrial fibrillation and optimally controlled ventricular rate are&#xD;
                  permitted&#xD;
&#xD;
               9. transient ischaemic attack, or stroke within 6 months prior to screening&#xD;
&#xD;
              10. patients with symptomatic hypotension at screening&#xD;
&#xD;
          -  Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features&#xD;
             suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).&#xD;
&#xD;
          -  Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to&#xD;
             swallow the formulated product or previous significant bowel resection that would&#xD;
             preclude adequate absorption of AZD5305&#xD;
&#xD;
          -  Known allergy or hypersensitivity to investigational product(s) or any of the&#xD;
             excipients of the investigational product(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Yap</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Modena</city>
        <zip>41125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARP inhibitor</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

